University of Ioannina
Ενεργότητα της paf - ακετυλοϋδρολάσης σε ασθενείς με διαταραχές του μεταβολισμού των λιποπρωτεϊνών πριν και μετά τη χορήγηση υπολιπιδαιμικών φαρμάκων
Abstract
dc:descriptionPAF-AH is a calcium independent phospholipase A2 that circulates in complex with lipoprotein particles. In human plasma, more than 90% of enzymatic activity is associated with low density lipoproteins (LDL) and the remainder with high density lipoproteins (HDL). Thus, the term plasma PAF-AH mainly reflects the LDL-associated proportion of the enzyme. Except for PAF, the enzyme can also effectively hydrolyze oxidized phospholipids with short acyl chains at sn-2 position. These phospholipids are formed during the oxidative modification of LDL and possibly contribute to their proinflammatory properties. From a pathophysiological point of view, PAF-AH may play either an antiatherogenic role (since it degrades PAF and oxidized phospholipids) or a proatherogenic role (since it generates lyso-PC and oxidized fatty acids, molecules that have been reported to exert several proinflammatory properties). The clinical studies that evaluated the role of PAF-AH in the pathogenesis of atherosclerosis failed to reveal consistent results. Thus, other studies have shown that patients with cardiovascular disease exhibit significantly higher plasma enzymatic activity as compared to healthy individuals, whereas recent studies in Japanese patients concluded that the loss of plasma enzymatic activity due to G994—»T mutation is a risk factor for ischemic events. However, a recent analysis of WOSCOPS data revealed that plasma PAF-AH is an independent risk factor for the development of cardiovascular disease. On the other hand, the HDL-associated proportion of the enzyme clearly plays an antiatherogenic role, since it protects LDL from oxidation and diminishes the biological action of oxidized LDL. The aim of this study was to determine and compare the PAF-AH activities in patients with different forms of primary dyslipidemias and to evaluate the effects of hypolipidemic drugs on plasma and HDL-associated enzymatic activity. Two hundred and seventy-five unrelated patients attending the outpatient Lipid Clinic of the University Hospital of Ioannina were screened. Secondary causes of dyslipidemia were excluded by history, clinical examination and appropriate laboratory tests. All patients instructed to follow a low fat-low cholesterol diet for at least 3 months. At the end of this period, all patients with abnormal lipid levels were included in the study. According to their baseline lipid values patients were subdivided into primary hypercholesterolemia or dyslipidemia type ILA group, consisted of 141 patients, combined hyperlipidemia or dyslipidemia type IIB group, of 84 patients, and hypertriglyceridemia or dyslipidemia type IV group of 50 patients. Furthermore, patients with138primary hypercholesterolemia were divided according to the underlying genetic defect into patients with homozygous familial hypercholesterolemia (HomoFH, n=5), patients with heterozygous familial hypercholesterolemia (HeteroFH, n=38), and patients with polygenic non-familial hypercholesterolemia (NonFH, n=98). Seventy-six patients received atorvastatin (55 type IIA and 21 type IIB patients), whereas 71 patients received fenofibrate (18 patients with type IIA dyslipidemia, 23 patients with type IIB dyslipidemia and 30 patients with type IV dyslipidemia). Serum lipid parameters and enzymatic activities were determined at baseline as well as after 16 weeks of active treatment. PAF-AH was measured in total plasma (for the determination of plasma PAF-AH), in HDL isolated after the precipitation ofapoB containing lipoproteins (for the determination ofHDL-associated PAF-AH) and in lipoprotein subtractions obtained by density gradient ultracentrifugation. All patient groups exhibited significantly higher plasma PAF-AH activity as compared to normolipidemic controls. In addition, patients with type IIA and type IIB dyslipidemia exhibited higher enzymatic activity as compared to type IV patients. Both type IIB and IV patients had significantly lower HDL-associated PAF-AH activity as compared to either type IIA or control group. In contrast, type IIA patients exhibited similar HDL-associated enzymatic activity with control individuals. Finally, all patient groups had significantly lower ratios of HDL-associated PAF-AH to LDL-cholesterol compared with control individuals. Subfractionation of apoB-containing lipoproteins revealed that in all study groups the greater proportion of PAF-AH activity was preferentially associated with small, dense LDL subtractions. Type IIA and IIB patients exhibited significantly higher enzymatic activity in all LDL subtractions as compared to type IV patients and control individuals. Additionally, type IIB and IV patients had higher enzymatic activities in VLDL+IDL subtractions as compared to control group. Among HDL subspecies PAF-AH was preferentially associated with dense HDL subffactions in all patient groups. Patients with type IIB and type IV dyslipidemias had significantly lower enzymatic activity in this subtraction as compared to controls, whereas type IIA patients had similar values with normolipidemic individuals. Finally, no differences were observed in PAF-AH activity associated with the other HDL subtractions among study groups. In all patient groups with primary hypercholesterolemia (type ILA dyslipidemia) the plasma PAF-AH activity was significantly elevated compared to controls, the HomoFH having the highest and the NonFH patients the lowest enzyme activity. Gradient ultracentrifugation studies showed that this increase was not only due to the elevation in the plasma LDL-cholesterol, but also to the increase in the PAF-AH specific activity in each LDL subtraction, being more139profound in the small-dense LDL-5. Unlike LDL, no difference in HDL-associated PAF-AH activity (expressed per mL of plasma) was observed among all groups. Consequently, an altered distribution of enzymatic activity among apo B- and apo AI-containing lipoproteins was observed in hypercholesterolemic patients, resulting in a significant decrease in the ratio of the HDL-associated PAF-AH to the total plasma enzyme activity compared to controls. This reduction is proportional to the increase of the plasma LDL-cholesterol levels and consequently to the severity of the hypercholesterolemia, being more profound in HomoFH patients. Atorvastatin and fenofibrate administration induced a significant reduction in plasma PAF-AH activity in all groups studied. However, the responsible mechanism for this reduction was different for each drug and was affected by the underlying defect in the lipoproteins metabolism. Specifically, atorvastatin induced a significant decrease in the enzymatic activity asssociated with all LDL subtractions in type IIA and type IIB patients. In contrast, fenofibrate administration resulted in a significant reduction in PAF-AH activity associated with small, dense LDL subtractions in all patient groups without affecting the enzymatic activity in large and intermediate density subfractions. The reduction in plasma PAF-AH activity in type IV patients after fenofibrate administration was mainly due to the reduction in enzymatic activity associated with VLDL+IDL subfractions. This phenomenon was also observed (although to a lesser extent) in type IIB patients. Although atorvastatin did not significantly affect HDL-associated PAF-AH activity in type IIA and type IIB patients, fenofibrate induced an increase in HDL-associated enzymatic activity in type IIB and IV patients, whereas it did not affect the enzymatic activity in type IIA patients. This increase was due to an elevation in enzymatic activity associated with dense HDL subfractions whereas the enzymatic activity in the other HDL subspecies was not significantly affected. Finally, fenofibrate and atorvastatin induced a significant increase in the ratio of HDL-associated PAF-AH to LDL-cholesterol in all patient groups. In conclusion patients with different forms of primary dyslipidemias exhibit significantly higher plasma PAF-AH activity as compared to healthy population. In addition, patients with type IIB and type IV dyslipidemia have lower HDL-associated enzymatic activity as compared to controls, whereas all patient groups possess diminished protective potency of HDL against the LDL proatherogenic properties. These alterations may contribute to the increased incidence of cardiovascular disease in patients with primary dyslipidemias. The reductions in plasma PAF-AH activity in all patient groups after atorvastatin and fenofibrate administration as well as the fenofibrate-induced increase in HDL-associated PAF-AH activity in patients with type140IIB and type IV dyslipidemia represent new additional mechanisms of action of these potent hypolipidemic drugs and may contribute to their antiatherogenic and antiinflammatory functions.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsimichodimos, Vasilios
- Τσιμιχοδήμος, Βασίλειος
Subjects
dc:subject × 16- PAF-ακετυλοϋδρολάση ( PAF - AH)
- Υπερχοληστερολαιμία, οικογενής
- Δυσλιπιδαιμίες, Μικτή
- Υπερτριγλυκεριδαιμία
- Ατορβαστατίνη
- Φενοφιβράτη
- PAF - Acetylhydrolase ( PAF-AH)
- Hypercholesterolemia, Familial
- Dyslipidemia, Combined
- Hypertriglyceridemia
- Atorvastatin
- Fenofibrate
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21147